JP2007503834A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503834A5
JP2007503834A5 JP2006525474A JP2006525474A JP2007503834A5 JP 2007503834 A5 JP2007503834 A5 JP 2007503834A5 JP 2006525474 A JP2006525474 A JP 2006525474A JP 2006525474 A JP2006525474 A JP 2006525474A JP 2007503834 A5 JP2007503834 A5 JP 2007503834A5
Authority
JP
Japan
Prior art keywords
expression vector
continuation
vector according
alvac
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007503834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028751 external-priority patent/WO2005026370A2/en
Publication of JP2007503834A publication Critical patent/JP2007503834A/ja
Publication of JP2007503834A5 publication Critical patent/JP2007503834A5/ja
Pending legal-status Critical Current

Links

Images

JP2006525474A 2003-09-05 2004-09-03 黒色腫用の多抗原ベクター Pending JP2007503834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50057203P 2003-09-05 2003-09-05
US50400703P 2003-09-18 2003-09-18
PCT/US2004/028751 WO2005026370A2 (en) 2003-09-05 2004-09-03 Multi-antigen vectors for melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010257738A Division JP5373747B2 (ja) 2003-09-05 2010-11-18 黒色腫用の多抗原ベクター

Publications (2)

Publication Number Publication Date
JP2007503834A JP2007503834A (ja) 2007-03-01
JP2007503834A5 true JP2007503834A5 (enExample) 2007-10-11

Family

ID=34316448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525474A Pending JP2007503834A (ja) 2003-09-05 2004-09-03 黒色腫用の多抗原ベクター
JP2010257738A Expired - Fee Related JP5373747B2 (ja) 2003-09-05 2010-11-18 黒色腫用の多抗原ベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010257738A Expired - Fee Related JP5373747B2 (ja) 2003-09-05 2010-11-18 黒色腫用の多抗原ベクター

Country Status (9)

Country Link
US (1) US8911991B2 (enExample)
EP (1) EP1660119A2 (enExample)
JP (2) JP2007503834A (enExample)
KR (1) KR101141951B1 (enExample)
AU (2) AU2004273034A1 (enExample)
BR (1) BRPI0413334A (enExample)
CA (1) CA2537931A1 (enExample)
IL (1) IL173637A0 (enExample)
WO (1) WO2005026370A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US20060217893A1 (en) * 2005-01-07 2006-09-28 Yanbin Li Method for detecting an unknown contaminant concentration in a substance
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
WO2008028124A1 (en) * 2006-09-01 2008-03-06 The Board Of Trustees Of The University Of Arkansas Methods and systems for detection of contaminants
WO2009042773A1 (en) * 2007-09-25 2009-04-02 University Of Miami Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons
WO2011140284A2 (en) * 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
TWI733719B (zh) * 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
US11564944B2 (en) 2016-11-21 2023-01-31 Nant Holdings Ip, Llc Fractal combination therapy
WO2021101510A1 (en) 2019-11-18 2021-05-27 Google Llc Privacy-aware meeting room transcription from audio-visual stream

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789774A2 (en) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6770456B1 (en) * 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1137792B9 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
WO2001030382A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1282702B1 (en) * 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
CA2429721A1 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2003080800A2 (en) * 2002-03-20 2003-10-02 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003095642A2 (en) * 2002-05-07 2003-11-20 Aventis Pasteur, Ltd. Polyepitopes and mini-genes for cancer treatment

Similar Documents

Publication Publication Date Title
JP2007503834A5 (enExample)
EP1320379B1 (en) Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
EP0979284B1 (en) Reagents for vaccination which generate a cd8 t cell immune response
Ivory et al. DNA vaccines: designing strategies against parasitic infections
AU2001286109A1 (en) Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen
US20020044948A1 (en) Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1108035B1 (en) Treatment of cervical cancer
US7273605B2 (en) Vaccine
US20030138454A1 (en) Vaccination method
Audibert Adjuvants for vaccines, a quest
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
CA2527640A1 (en) Tumor antigens for prevention and/or treatment of cancer
JP2011506497A5 (enExample)
Yu et al. DNA vaccines for cancer too
JP2010523138A5 (enExample)
AU2017236578B2 (en) HCV vaccines
Toes et al. Activation or frustration of anti-tumor responses by T-cell-based immune modulation
WO1998015285A9 (en) Methods and compositions for inducing a protective immune response to cancers
AU775973B2 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
Mizzen et al. Heat shock protein fusions: a platform for the induction of antigen-specific immunity
Holt et al. Critical Dependence of the Peptide Delivery Method on the Efficacy of Epitope Focused